PHYSIOL
ActiveSummary
PHYSIOL has been active since 1986 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €78.4m and a net result of €13.6m. Equity is growing by about 20% per year across the filed financial years. Its solvency ranks better than 30% of 91 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Financials · financial year 2025, full format
In the rankings
#1 company by total assets in Liège, Manufacturing sector#2 company by equity in Liège, Manufacturing sector#3 oldest company in the province of Liège, Pharmaceuticals sector
Turnover
€66.4m▲ 16.1%
2024 · €57.2m
EBIT margin
33.8%▼ 18.3pp
2024 · 52.1%
Net result
€13.6m▼ 25.3%
2024 · €18.3m
Working capital
€33.9m▼ 11.3%
2024 · €38.3m
Trend over the years
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
The operating result falls in 2025; 2025 is 25% below 2024.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
Turnover€66.4m
2025
Operating result€22.5m
2025
Net result€13.6m
2025
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Total assets€245.1m
2025
Equity€78.4m
2025
Debt€166.7m
2025
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Working capital€33.9m
2025
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
EBIT margin33.8%
2025
Return on assets (ROA)5.6%
2025
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Solvency32.0%
2025
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Current ratio2.11
2025
Average staff in full-time equivalents (FTE).
Staff (FTE)159.1
2025
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Turnover€56.1m-€59.3m▲ 5.7%€55.4m▼ 6.6%€63.2m▲ 14.2%€81.7m▲ 29.1%€66.5m▼ 18.6%€57.2m▼ 14.0%€66.4m▲ 16.1%
Operating result€28.9m-€28.1m▼ 2.7%€24.7m▼ 12.0%€23.7m▼ 4.0%€30.0m▲ 26.4%€21.0m▼ 30.0%€29.8m▲ 42.1%€22.5m▼ 24.7%
Net result€26.7m-€23.4m▼ 12.3%€17.4mabove the sector's middle half▼ 25.4%€17.0mabove the sector's middle half▼ 2.7%€22.5mabove the sector's middle half▲ 32.7%€9.1mabove the sector's middle half▼ 59.7%€18.3mabove the sector's middle half▲ 101%€13.6mabove the sector's middle half▼ 25.3%
EBIT margin51.4%-47.4%▼ 4.1pp44.6%▼ 2.7pp37.5%▼ 7.1pp36.7%▼ 0.8pp31.5%▼ 5.2pp52.1%▲ 20.6pp33.8%▼ 18.3pp
Equity€29.9m-€53.1m▲ 77.2%€70.3mabove the sector's middle half▲ 32.6%€87.2mabove the sector's middle half▲ 24.0%€109.6mabove the sector's middle half▲ 25.8%€118.7mabove the sector's middle half▲ 8.2%€64.8mabove the sector's middle half▼ 45.4%€78.4mabove the sector's middle half▲ 21.0%
Total assets€46.5m-€196.5m▲ 322%€222.9mabove the sector's middle half▲ 13.4%€252.2mabove the sector's middle half▲ 13.1%€290.7mabove the sector's middle half▲ 15.3%€317.3mabove the sector's middle half▲ 9.2%€248.8mabove the sector's middle half▼ 21.6%€245.1mabove the sector's middle half▼ 1.5%
Debt€16.2m-€143.4m▲ 786%€152.6m▲ 6.4%€165.0m▲ 8.1%€181.0m▲ 9.7%€198.4m▲ 9.6%€184.0m▼ 7.2%€166.7m▼ 9.4%
Working capital€10.0m-€22.3m▲ 123%€28.7mabove the sector's middle half▲ 28.5%€32.3mabove the sector's middle half▲ 12.9%€25.0mabove the sector's middle half▼ 22.6%€41.6mabove the sector's middle half▲ 66.0%€38.3mabove the sector's middle half▼ 7.9%€33.9mabove the sector's middle half▼ 11.3%
Solvency64.4%-27.0%▼ 37.4pp31.6%within the sector's middle half▲ 4.5pp34.6%within the sector's middle half▲ 3.0pp37.7%within the sector's middle half▲ 3.1pp37.4%within the sector's middle half▼ 0.3pp26.1%within the sector's middle half▼ 11.4pp32.0%within the sector's middle half▲ 5.9pp
Current ratio1.62-2.90▲ 1.283.13above the sector's middle half▲ 0.232.80within the sector's middle half▼ 0.331.51within the sector's middle half▼ 1.291.87within the sector's middle half▲ 0.362.14within the sector's middle half▲ 0.272.11within the sector's middle half▼ 0.03
Return on assets (ROA)57.3%-11.9%▼ 45.4pp7.8%above the sector's middle half▼ 4.1pp6.7%within the sector's middle half▼ 1.1pp7.7%above the sector's middle half▲ 1.0pp2.9%within the sector's middle half▼ 4.9pp7.3%within the sector's middle half▲ 4.5pp5.6%within the sector's middle half▼ 1.8pp
Staff (FTE)125-153.9▲ 23.1%172.5above the sector's middle half▲ 12.1%175.8above the sector's middle half▲ 1.9%191.2above the sector's middle half▲ 8.8%185.5above the sector's middle half▼ 3.0%173.5above the sector's middle half▼ 6.5%159.1above the sector's middle half▼ 8.3%
above
within
below
the middle half of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €245.1m
Fixed assets
€180.7m ▲ 2.1%
Current assets
€64.5m ▼ 10.2%
Equity and liabilities €245.1m
Equity
€78.4m ▲ 21.0%
Debt
€166.7m ▼ 9.4%
Debt's share of the balance-sheet total falls from 73.9% to 68.0%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€25.7m▼
2024 · €32.0m
Cash flow
€16.8m▼
2024 · €20.4m
Quick ratio
1.61▼
2024 · 1.79
Debt to equity
2.13▼
2024 · 2.84
ROE
17.4%▼
2024 · 28.2%
Interest coverage
2.78▲
2024 · 1.74
Debt ≤ 1 year
€30.5m▼
2024 · €33.5m
Debt > 1 year
€136.2m▼
2024 · €150.5m
Income taxes
€1.0m▼
2024 · €3.2m
Staff costs
€13.2m▼
2024 · €13.5m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Operating income70/76A | - | - | - | €64.2m | €84.1m | €67.1m | €62.8m | €73.0m | ▲ 16.2% |
| Turnover70 | €56.1m | €59.3m | €55.4m | €63.2m | €81.7m | €66.5m | €57.2m | €66.4m | ▲ 16.1% |
| Change in stocks of work in progress, finished goods and contracts in progress71 | - | - | - | -€1.5m | -€0.3m | -€2.0m | -€2.4m | €2.4m | - |
| Own construction capitalised72 | - | - | - | - | - | - | €5.4m | €2.2m | ▼ 58.8% |
| Other operating income74 | - | - | - | €2.5m | €2.8m | €2.6m | €2.6m | €1.9m | ▼ 26.8% |
| Operating charges60/66A | - | - | - | €40.5m | €54.1m | €46.2m | €33.0m | €50.5m | ▲ 53.2% |
| Goods for resale, raw materials and consumables60 | - | - | - | €7.9m | €21.3m | €11.3m | €2.0m | €16.1m | ▲ 690% |
| Purchases600/8 | - | - | - | €11.1m | €21.5m | €12.7m | €0.6m | €17.1m | ▲ 2,757% |
| Change in stocks: decrease (increase)609 | - | - | - | -€3.3m | -€0.1m | -€1.4m | €1.4m | -€1.0m | - |
| Services and other goods61 | - | - | - | €15.6m | €18.2m | €18.3m | €16.5m | €18.4m | ▲ 11.8% |
| Remuneration, social security and pensions62 | - | - | - | €11.9m | €15.2m | €15.4m | €13.5m | €13.2m | ▼ 2.8% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €2.4m | €3.1m | €2.3m | €1.9m | €1.5m | €0.9m | €2.1m | €3.2m | ▲ 50.5% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | - | €3.2m | -€2.1m | -€0.03m | -€1.1m | -€0.5m | ▲ 52.6% |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | - | - | - | - | - | €0.3m | -€0.3m | - | - |
| Other operating charges640/8 | - | - | - | €0.08m | €0.08m | €0.1m | €0.1m | €0.2m | ▲ 38.8% |
| Operating profit (loss)9901 | €28.9m | €28.1m | €24.7m | €23.7m | €30.0m | €21.0m | €29.8m | €22.5m | ▼ 24.7% |
| Financial income75/76B | - | - | - | €2.8m | €4.0m | €9.1m | €10.3m | €1.9m | ▼ 81.4% |
| Recurring financial income75 | €0.7m | €0.7m | €1.7m | €2.8m | €4.0m | €9.1m | €10.3m | €1.9m | ▼ 81.4% |
| Income from financial fixed assets750 | - | - | - | €2.6m | €3.7m | €8.2m | €9.9m | €1.4m | ▼ 85.7% |
| Income from current assets751 | - | - | - | €70 | - | - | - | - | - |
| Other financial income752/9 | - | - | - | €0.1m | €0.4m | €0.9m | €0.4m | €0.5m | ▲ 29.2% |
| Financial charges65/66B | - | - | - | €8.2m | €8.3m | €18.2m | €18.6m | €9.7m | ▼ 47.9% |
| Recurring financial charges65 | €0.2m | €3.7m | €8.0m | €8.2m | €8.3m | €18.0m | €18.6m | €9.7m | ▼ 48.0% |
| Debt charges650 | €3 | €3.6m | €8.0m | €8.0m | €8.2m | €17.8m | €18.4m | €9.2m | ▼ 49.6% |
| Other financial charges652/9 | - | - | - | €0.2m | €0.2m | €0.2m | €0.3m | €0.4m | ▲ 56.0% |
| Non-recurring financial charges66B | - | - | - | - | €0.007m | €0.2m | €0.001m | €0.01m | ▲ 1,336% |
| Profit (loss) for the period before taxes9903 | €29.4m | €25.1m | €18.4m | €18.3m | €25.7m | €11.9m | €21.5m | €14.7m | ▼ 31.7% |
| Income taxes67/77 | €2.7m | €1.8m | €1.0m | €1.3m | €3.1m | €2.8m | €3.2m | €1.0m | ▼ 68.2% |
| Taxes670/3 | - | - | - | €1.3m | €3.1m | €2.8m | €3.2m | €1.0m | ▼ 68.2% |
| Profit (loss) for the period9904 | €26.7m | €23.4m | €17.4m | €17.0m | €22.5m | €9.1m | €18.3m | €13.6m | ▼ 25.3% |
| Transfer from tax-exempt reserves789 | - | - | - | €0.7m | - | - | - | - | - |
| Profit (loss) for the period to be appropriated9905 | €26.7m | €23.4m | €18.2m | €17.7m | €22.5m | €9.1m | €18.3m | €13.6m | ▼ 25.3% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €46.5m | €196.5m | €222.9m | €252.2m | €290.7m | €317.3m | €248.8m | €245.1m | ▼ 1.5% |
| Fixed assets21/28 | €20.3m | €162.5m | €180.8m | €201.8m | €216.2m | €227.8m | €177.0m | €180.7m | ▲ 2.1% |
| Intangible fixed assets21 | €0.5m | €0.4m | €0.4m | €0.2m | €0.1m | €0.1m | €4.3m | €4.1m | ▼ 3.6% |
| Tangible fixed assets22/27 | €7.4m | €7.1m | €6.1m | €5.7m | €7.1m | €7.6m | €7.8m | €8.1m | ▲ 3.7% |
| Land and buildings22 | - | - | - | €2.4m | €2.1m | €4.6m | €4.2m | €3.9m | ▼ 7.1% |
| Plant, machinery and equipment23 | - | - | - | €2.3m | €1.5m | €2.3m | €2.4m | €3.7m | ▲ 58.2% |
| Furniture and vehicles24 | - | - | - | €0.6m | €0.5m | €0.5m | €0.4m | €0.4m | ▼ 12.5% |
| Leasing and similar rights25 | - | - | - | €0.09m | €0.08m | €0.07m | - | - | - |
| Assets under construction and advance payments27 | - | - | - | €0.4m | €2.9m | €0.1m | €0.8m | €0.05m | ▼ 93.6% |
| Financial fixed assets28 | €12.4m | €154.9m | €174.4m | €195.8m | €208.9m | €220.1m | €164.9m | €168.5m | ▲ 2.1% |
| Affiliated companies280/1 | - | - | - | €195.8m | €208.9m | €220.0m | €164.9m | €168.4m | ▲ 2.1% |
| Participating interests280 | - | - | - | €143.4m | €143.9m | €143.9m | €144.2m | €144.2m | = |
| Amounts receivable281 | - | - | - | €52.5m | €65.0m | €76.1m | €20.8m | €24.3m | ▲ 16.9% |
| Other financial fixed assets284/8 | - | - | - | €0.01m | €0.02m | €0.02m | €0.004m | €0.004m | = |
| Amounts receivable and cash guarantees285/8 | - | - | - | €0.01m | €0.02m | €0.02m | €0.004m | €0.004m | = |
| Current assets29/58 | €26.2m | €34.0m | €42.1m | €50.3m | €74.5m | €89.5m | €71.8m | €64.5m | ▼ 10.2% |
| Stocks and contracts in progress3 | €6.2m | €8.5m | €14.3m | €12.8m | €14.7m | €14.8m | €11.6m | €15.2m | ▲ 30.3% |
| Stocks30/36 | - | - | - | €12.8m | €14.7m | €14.8m | €11.6m | €15.2m | ▲ 30.3% |
| Raw materials and consumables30/31 | - | - | - | €2.0m | €2.5m | €2.6m | €1.8m | €2.2m | ▲ 21.7% |
| Work in progress32 | - | - | - | €0.4m | €0.6m | €0.9m | €1.2m | €1.8m | ▲ 49.4% |
| Finished goods33 | - | - | - | €8.8m | €10.3m | €8.8m | €6.8m | €8.6m | ▲ 26.2% |
| Goods purchased for resale34 | - | - | - | €1.5m | €1.4m | €2.5m | €1.8m | €2.6m | ▲ 41.9% |
| Amounts receivable within one year40/41 | €15.9m | €22.6m | €19.4m | €28.4m | €58.0m | €73.7m | €56.3m | €46.0m | ▼ 18.3% |
| Trade receivables40 | - | - | - | €27.0m | €51.2m | €65.4m | €54.0m | €45.3m | ▼ 16.2% |
| Other amounts receivable41 | - | - | - | €1.4m | €6.8m | €8.2m | €2.3m | €0.7m | ▼ 68.9% |
| Cash at bank and in hand54/58 | €4.0m | €2.4m | €6.6m | €4.7m | €1.7m | €0.9m | €3.7m | €3.2m | ▼ 13.0% |
| Deferred charges and accrued income490/1 | - | - | - | €4.5m | €0.1m | €0.1m | €0.2m | €0.1m | ▼ 46.3% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €46.5m | €196.5m | €222.9m | €252.2m | €290.7m | €317.3m | €248.8m | €245.1m | ▼ 1.5% |
| Equity10/15 | €29.9m | €53.1m | €70.3m | €87.2m | €109.6m | €118.7m | €64.8m | €78.4m | ▲ 21.0% |
| Contributions10/11 | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | = |
| Capital10 | - | - | - | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | = |
| Issued capital100 | - | - | - | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | = |
| Reserves13 | €1.6m | €1.6m | €1.6m | €1.6m | €1.6m | €1.6m | €1.6m | €1.6m | = |
| Non-distributable reserves130/1 | - | - | - | €0.09m | €0.09m | €0.09m | €0.09m | €0.09m | = |
| Legal reserve130 | - | - | - | €0.09m | €0.09m | €0.09m | €0.09m | €0.09m | = |
| Distributable reserves133 | - | - | - | €1.5m | €1.5m | €1.5m | €1.5m | €1.5m | = |
| Profit (loss) carried forward14 | €26.8m | €50.2m | €67.6m | €84.6m | €107.1m | €116.1m | €62.3m | €75.9m | ▲ 21.9% |
| Investment grants15 | - | - | - | €0.2m | €0.1m | €0.1m | €0.09m | €0.07m | ▼ 21.1% |
| Provisions and deferred taxes16 | €0.4m | - | - | - | - | €0.3m | - | - | - |
| Provisions for liabilities and charges160/5 | - | - | - | - | - | €0.3m | - | - | - |
| Other liabilities and charges164/5 | - | - | - | - | - | €0.3m | - | - | - |
| Amounts payable17/49 | €16.2m | €143.4m | €152.6m | €165.0m | €181.0m | €198.4m | €184.0m | €166.7m | ▼ 9.4% |
| Amounts payable after more than one year17 | - | €128.2m | €131.6m | €131.6m | €131.6m | €150.4m | €150.5m | €136.2m | ▼ 9.5% |
| Financial debts170/4 | - | - | - | €131.6m | €131.6m | €150.4m | €150.5m | €136.2m | ▼ 9.5% |
| Unsubordinated bonds171 | - | - | - | €128.2m | €128.2m | €146.5m | €145.5m | €130.9m | ▼ 10.1% |
| Other loans174 | - | - | - | €3.4m | €3.4m | €3.9m | €4.9m | €5.3m | ▲ 7.5% |
| Amounts payable within one year42/48 | €16.2m | €11.7m | €13.5m | €18.0m | €49.5m | €48.0m | €33.5m | €30.5m | ▼ 9.0% |
| Current portion of amounts payable after more than one year42 | - | - | - | €0.02m | - | - | - | - | - |
| Financial debts43 | - | - | - | - | - | €2.5m | €3.8m | €2.3m | ▼ 38.8% |
| Credit institutions430/8 | - | - | - | - | - | €2.5m | €3.8m | €2.3m | ▼ 38.8% |
| Trade debts44 | €8.4m | €9.4m | €10.8m | €15.3m | €25.9m | €28.5m | €21.0m | €21.9m | ▲ 4.1% |
| Suppliers440/4 | - | - | - | €15.3m | €25.9m | €28.5m | €21.0m | €21.9m | ▲ 4.1% |
| Advances received on contracts in progress46 | - | - | - | - | - | - | €1.1m | - | - |
| Taxes, remuneration and social security45 | - | - | - | €2.7m | €4.8m | €5.4m | €7.3m | €6.1m | ▼ 15.8% |
| Taxes450/3 | - | - | - | €0.3m | €1.6m | €3.0m | €5.3m | €4.7m | ▼ 12.1% |
| Remuneration and social security454/9 | - | - | - | €2.4m | €3.2m | €2.4m | €2.0m | €1.5m | ▼ 25.9% |
| Other amounts payable47/48 | - | - | - | €0.02m | €18.8m | €11.5m | €0.3m | €0.2m | ▼ 43.6% |
| Accrued charges and deferred income492/3 | - | - | - | €15.4m | €0.001m | €0.02m | - | - | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €26.7m | €23.4m | €17.4m | €17.0m | €22.5m | €9.1m | €18.3m | €13.6m | ▼ 25.3% |
| + Depreciation and write-downs630 | €2.4m | €3.1m | €2.3m | €1.9m | €1.5m | €0.9m | €2.1m | €3.2m | ▲ 50.5% |
| Operating cash flow (approximation) | €29.0m | €26.4m | €19.8m | €18.9m | €24.0m | €9.9m | €20.4m | €16.8m | ▼ 17.4% |
| Investment in fixed assets (approximation) | - | -€145.2m | -€20.7m | -€22.9m | -€15.8m | -€12.5m | €48.6m | -€6.9m | - |
| Change in cash | - | -€1.6m | €4.1m | -€1.9m | -€3.0m | -€0.8m | €2.7m | -€0.5m | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Latest 10 of 40 filings with the National Bank
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | full format | 30-06-2026 | 2026-00249048 |
| 31-12-2024 | full format | 30-06-2025 | 2025-00204727 |
| 31-12-2023 | full format | 11-07-2024 | 2024-00241372 |
| 31-12-2022 | full format | 07-07-2023 | 2023-00217886 |
| 31-12-2021 | full format | 23-06-2022 | 2022-20091754 |
| 31-12-2020 | full format | 09-07-2021 | 2021-34900196 |
| 31-12-2019 | full format | 27-08-2020 | 2020-45700025 |
| 31-12-2018 | full format | 24-07-2019 | 2019-37200020 |
| 31-12-2017 | full format | 10-07-2018 | 2018-30400199 |
| 31-12-2016 | full format | 06-07-2017 | 2017-27900513 |
Similar companies · same sector, comparable size
ODYSSEA PHARMA
BE 0892.121.272
Grâce-Hollogne · equity €76.4m
Novo Nordisk Production Belgium SA
BE 0465.935.738
Brussel · equity €74.2m
BAXTER
BE 0403.093.693
Lessines · equity €83.8m
Pfizer
BE 0401.994.823
Elsene · equity €90.4m
ROCHE
BE 0403.088.151
Anderlecht · equity €64.5m
Of the 149 active companies whose main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201), figures are known for 120. 38 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector
Public contracts
6 awards · 2024 to 2025
RAAMOVEREENKOMST VOOR DE AANKOOP VAN INTRA-OCULAIRE LENZEN, VERBONDEN VERBRUIKSGOEDEREN EN OFTALMOLOGISCH VISCO-ELASTISCH PRODUCT: HHM/2024/RE/AD-lenzen - 1
RAAMOVEREENKOMST VOOR DE AANKOOP VAN INTRA-OCULAIRE LENZEN, VERBONDEN VERBRUIKSGOEDEREN EN OFTALMOLOGISCH VISCO-ELASTISCH PRODUCT: HHM/2024/RE/AD-lenzen - 4
RAAMOVEREENKOMST VOOR HET LEVEREN VAN LENZEN, VISCO-ELASTISCH PRODUCT EN CUSTOMPACKS VOOR HET AZ JAN PALFIJN ZIEKENHUIS GENT.: APO-2023-14. - 1 intra oculaire lenzen (IOL) en visco-elastisch product
RAAMOVEREENKOMST VOOR HET LEVEREN VAN LENZEN, VISCO-ELASTISCH PRODUCT EN CUSTOMPACKS VOOR HET AZ JAN PALFIJN ZIEKENHUIS GENT.: APO-2023-14. - 3 custom packs oogheelkunde
Accord-cadre de fournitures ayant pour objet la fourniture de customs packs cataracte/vitrectomie, canules I/A et couteaux: Customs packs cataracte et vitrectomie
Show 1 more contract
Accord-cadre de fournitures ayant pour objet la fourniture de customs packs cataracte/vitrectomie, canules I/A et couteaux: Couteaux
Source: TED (Tenders Electronic Daily), Publications Office of the European Union. Values as the buyer published them; for a framework agreement, a ceiling.